Skip to content

SCRIPTOCOCCUS

Active
Private limited company· 27 yrs active
Avenue de la Paix 20 ·1330 Rixensart, Belgium
KBO/BCE: BE 0466.063.422
Watch Print / PDF
Full dossier in preparation

Checked processes every Belgian company, act by act, from the Belgian Official Gazette. The data below is real and verified, this company's full, act-by-act verified dossier is still being assembled.

Process with priority Sign in free to move this company to the front.
Age27 yrs
Board1

Summary

Conclusion

the dossier summarised in one paragraph

The computed 12-month bankruptcy probability of SCRIPTOCOCCUS is 0.8% (low). The 2025 annual accounts show equity of €139k and a net result of €7k. Equity is shrinking by ~6.5% per year across the filed fiscal years. The company has been active since 1999 and the Belgian State Gazette contains no insolvency or warning signals.

Based on the State Gazette, CBE and 8 annual accounts.

Signals

1 signal · with evidence
Consistently profitable
Positive net result in the two most recent financial years (2024 and 2025).
View the result trend

Signals are derived from the filed annual accounts and the sector comparison. No composite score: each signal is separately verifiable at the source.

Trust signals

2 signals
Long-established
Founded in 1999, 27 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.

Administrative Flags

No administrative flags

Bankruptcy probability (12 mo)

Checked model v1 · free for everyone
0.8% Low
0%0,5%1,5%4%10%≥25%
No NACE activity registered +Long track record Annual accounts: healthy financial profile

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Financials

TurnoverNot published (abbreviated filing)
EBIT marginNot published (abbreviated filing)
Net result€7k-46.0%
Working capital€122k-8.8%

Annual accounts & ratios

Source: NBB · 2025
Annual accounts filed on 20-05-2026 with the NBB · fiscal year 2025 · micro
€-20k€0€20k€40kOperating result 2021: €25k€25kNet result 2021: €17k€17kOperating result 2022: €-13k€-13kNet result 2022: €-14k€-14kOperating result 2023: €32k€32kNet result 2023: €26k€26kOperating result 2024: €22k€22kNet result 2024: €12k€12kOperating result 2025: €7k€7kNet result 2025: €7k€7k20212022202320242025
Operating resultNet result
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
declining Equity: declining trend of ~6.5%/year over 8 fiscal years, indicative, assuming unchanged policy.
€50k€100k€150k€200k€250k2026: €138k (€117k - €158k)2027: €124k (€91k - €157k)2028: €110k (€65k - €155k)2018: €218k2019: €244k2020: €210k2021: €228k2022: €214k2023: €186k2024: €159k2025: €139k20182019202020212022202320242025202620272028
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?

The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.

The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.

A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).

EBITDA
€15k
-46.8% 18-25
Net profit
€7k
-46.0% 18-25
Cash flow
€14k
-21.1% 18-25
Total assets
€170k
-35.2% 18-25
Equity
€139k
-12.3% 18-25
Working capital
€122k
-8.8% 18-25
Income taxes
€724
-94.1% 18-25
Dividends
€26k
-33.8% 18-25
Debt
€31k
-70.4% 18-25
Debt ≤ 1y
€31k
-70.4% 18-25
Current ratio
5.00
+117.5% 18-25
Quick ratio
5.00
+117.5% 18-25
Solvency
82.0%
+35.4% 18-25
Debt / equity
0.22
-66.3% 18-25
ROE
4.8%
-38.4% 18-25
ROA
3.9%
-16.6% 18-25
Interest coverage
113.63
+3.3% 18-25
Figures by fiscal year
Fiscal year2025
Revenue-
EBITDA€15k
Net profit€7k
Cash flow€14k
Staff costs-
Income taxes€724
Dividends€26k
Total assets€170k
Equity€139k
Debt€31k
of which ≤ 1y€31k
of which > 1y-
Working capital€122k
Employees (FTE)-
Ratios (computed)
2025
Current ratio5.00
Quick ratio5.00
Working capital ratio71.9%
Solvency82.0%
Debt / equity0.22
Long-term debt ratio-
Interest coverage113.63
Gross margin-
Net margin-
ROA3.9%
ROE4.8%
EBITDA margin-
Days sales outstanding-
Days payable outstanding-
Inventory turnover-
Days inventory (DSI)-
Balance-sheet composition 2025
Full annual accounts
Filed balance sheet and income statement, exactly as deposited with the NBB.
Line item Code2025
Balance sheet, Assets
TOTAL ASSETS 20/58€170k
Fixed assets 21/28€17k
Tangible fixed assets 22/27€17k
Current assets 29/58€153k
Amounts receivable within one year 40/41€2k
Cash & bank 54/58€144k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES 10/49€170k
Equity 10/15€139k
Contributions / capital 10/11€6k
Reserves 13€133k
Accumulated profits (losses) 14€558
Amounts payable 17/49€31k
Amounts payable within one year 42/48€31k
Trade debts payable within one year 44€33
Income statement
Gross operating margin 9900€16k
Operating result 9901€7k
Financial income 75€322
Financial charges 65€132
Result before taxes 9903€7k
Income taxes 67/77€724
Net result for the period 9904€7k
Result to be appropriated 9905€7k
You're seeing the latest fiscal year only. Unlock 4 prior years (figures + ratios) with a paid plan. See plans →
Ratios computed by Checked.

Health barometer

FY 2025 · computed
83 / 100 Excellent
050100
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.

Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.

See plans →
Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.

Directors

Directors & mandates

1 director
Current directors & mandates
  • Philippe MAUCLET
    Director
    State Gazette act 22314383 (01-03-2022)
    Current
    01-03-2022 → present
Full appointment history from the Belgian State Gazette. Permanent representatives are shown for corporate directors.

Insolvency mandates

No insolvency mandates (liquidators, administrators) on record for this company.

Legal Structure

NACE primary -
Legal form Private limited company(610)
Incorporation17-05-1999
StatusActive
Postal code1330

Structure & network

Locations & real estate

Registered office

on the map · from the address register
seat.Municipality exact location from the address register
2 companies at this address See who is registered here

Establishment units

1 location
Avenue de la Paix 20, 1330 Rixensart
Activiteiten van huisartspraktijken
since 20032.113.903.578
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Parcels1
Ground area388 m²
Buildings1
Building footprint55 m²
Volume (LiDAR)426 m³
Tallest building9.0 m · ±3 fl.

Real-estate footprint

Source: CBE × cadastre · address linking

Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.

Wallonia 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
25091A0932/00A000 Wallonia 388 m² 1 · 55 m² 9.0 m · 3 fl.
Methodology
via registered seat: 1
1 of 1 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Publications

Lifecycle & Insolvency Signals

No insolvency signals in the Belgian State Gazette

Belgisch Staatsblad · acts

4 acts
Address history · 3
15-05-2026
Seat change: new_address: Avenue de la Paix 20 à 1330 Rixensart, old_address: Avenue Jean XXIII, 30 à 1330 Rixensart, effective_date: 2026-04-16
22-06-2018
v3.2
31-01-2018
v3.2
All acts · 4 updated 2 months ago
2026
15-05-2026 General meeting · Seat change · Power of attorney · Act object Open-capture extraction
  • Filing: 2026-05-15 · SCRIPTOCOCCUS
  • General meeting: 2026-04-16 · SCRIPTOCOCCUS
  • Seat change: new_address: Avenue de la Paix 20 à 1330 Rixensart, old_address: Avenue Jean XXIII, 30 à 1330 Rixensart, effective_date: 2026-04-16 · SCRIPTOCOCCUS
  • Power of attorney: date: 2026-04-16, purpose: accomplir les actes nécessaires à la publication dans les Annexes du Moniteur Belge de la présente décision, en ce compris procéder à la signature des formulaires de publications, representative: LIETARD_Aline · SCRIPTOCOCCUS
  • Publication: 2026-05-15
  • Act object: Modification du siège social
Summary: General meeting · Seat change · Power of attorney · Act object
2022
01-03-2022 Philippe MAUCLET reappointed as director Director changes
  • Philippe MAUCLET, Bestuurder
Summary: v3.2
2018
22-06-2018 Registered office moved from Louvain-La- Nowve to Rixensart Registered-office change
  • Avenue des Museccens 7, 1348 Louvain-La- Nowve → Avenue Jean XXI11 30, 1330 Rixensart
Summary: v3.2
31-01-2018 Registered office moved from Rixensart to Louvain-La-Neuve Registered-office change
  • Avenue de l'Europe 37, 1330 Rixensart → Avenue des Musiciens 7, 1348 Louvain-La-Neuve
Summary: v3.2

Analysis

Snowflake analysis

financial profile on 5 axes
Health83Profitability24Solvency100Growth32Stability100
68 / 100

Strong profile, led by solvency.

All 5 axes are computed from data Checked has read.

Health 83
Profitability 24
Solvency 100
Growth 32
Stability 100

Ask AI about this company

Checked AI

Soon: ask questions about this dossier, risks, curator, sector comparison, answered from the official data on this page.

TryWhat are the main risks?Any recent red flags?Compare to sector peers
Coming soon

AI due-diligence brief

Checked AI

Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.

Coming soon
The brief is drafted by our AI model at Anthropic in the US, from this dossier's public data. Nothing that identifies you is sent along and we do not keep the brief. Indicative, not legal or investment advice. How it works

Credit advice

verdict per customer and amount

Should this customer buy amount X on invoice? Enter the amount and payment terms, you get an instant GREEN/AMBER/RED verdict, with a suggested ceiling and concrete conditions.

Based on official sources (NBB, CBE, State Gazette). Indicative, not credit advice.

Company registry

Company registry (CBE)

Crossroads Bank
Names & trade names
Legal nameFR SCRIPTOCOCCUS
Registered office
Avenue de la Paix 20
1330 Rixensart, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.